
Please try another search
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for burn and ocular pain; and IMC-2, a combination of valacyclovir and celecoxib in Phase 2 clinical trial for the treatment of long-COVID and post-acute sequelae of COVID-19 infection. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is based in Alpharetta, Georgia.
Name | Age | Since | Title |
---|---|---|---|
Dedra Stefanie Buchwald | - | - | Member of Scientific Advisory Board |
Greg Duncan | 56 | 2018 | Chairman & CEO |
David R. Keefer | 70 | 2018 | Independent Director |
Richard James Whitley | 77 | 2020 | Member of Scientific Advisory Board & Independent Director |
Daniel J. Clauw | - | - | Chair of Scientific Advisory Board |
John C. Thomas | 69 | 2020 | Independent Director |
William L. Pridgen | 63 | 2012 | Founder & Member of Scientific Advisory Board |
Abel De La Rosa | 61 | 2020 | Independent Director |
Joel D. Baines | - | - | Member of Scientific Advisory Board |
Michael C. Camilleri | - | - | Member of Scientific Advisory Board |
Kean Meng Toh | 57 | 2024 | Director |
Lesley Mussio Arnold | - | - | Member of Scientific Advisory Board |
Ying Choi Yu | 68 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review